RELATIONSHIP BETWEEN TYPE AND INTENSITY OF ANTICOAGULANT THERAPY AND RECURRENCE OF ARTERIAL THROMBOSIS ON ANTIPOSPHOLIPID SYNDROME
(Abstract release date: 05/19/16)
EHA Library. Siguenza R. 06/09/16; 135115; PB2215
Dr. Raul Siguenza
Contributions
Contributions
Abstract
Abstract: PB2215
Type: Publication Only
Background
The optimal type and intensity of anticoagulant therapy for the treatment of Antipospholipid Syndrome (APS) remain controversial issues, particularly for arterial thrombosis.
Aims
We investigated if there are difference between the development of recurrence of arterial thrombosis on APS taking anticoagulant therapy with vitamin K antagonist (VKA), antiplatelet therapy with ASA, or both VKA and ASA.
Methods
Retrospective we investigated the development of recurrence arterial thrombosis in 23 patients consecutive diagnosed in our hospital of APS with previous arterial thrombosis, from 1 February 2000 to 31 December of 2015. The patients ages were between 25 to 88, gender 39.1% male and 60.9%. Patients were treated well with ASA 100 or 300 mg either VKA for objective 2.5 INR, adding or ASA 100 mg depending on the thrombotic risk (depending on the location of thrombosis and the presence of thrombophilia and established cardiovascular risk factors ). 10 patients present Stroke, including Cryptogenic Ischemic Stroke, 6 present Transient Ischemic Attack, 4 Myocardial Infarction, and 3 other periferical arterial thrombosis (ocular, laberintical and popliteal). Of this 23 patients, suffered recurrence arterial thrombosis 4 of 12 were taking AAS, 4 of 8 patients taking VKA, and 1 of 3 taking VKA and ASA.The statistical analysis was performed with Pearson test realized by JMP 9.
Results
We not found statistically significant difference between the APS patients taking VKA, ASA or VKA and AAS and the development of recurrence arterial thrombosis (OR 0.12, IC 95% -0.21 –0.46, p=0.73).
Conclusion
Although we found more patients with APS development recurrence arterial thrombosis taking AAS than VKA, we cannot establish an association between recurrence of arterial thrombosis and treatment without VKA. The location of thrombosis and the presence of classical cardiovascular risk factors do not seem to be good predictors of thrombotic recurrence. Future studies that delineate thrombotic risk in APS and evaluate current and novel anticoagulants as well as non anticoagulant therapies are required
Session topic: E-poster
Type: Publication Only
Background
The optimal type and intensity of anticoagulant therapy for the treatment of Antipospholipid Syndrome (APS) remain controversial issues, particularly for arterial thrombosis.
Aims
We investigated if there are difference between the development of recurrence of arterial thrombosis on APS taking anticoagulant therapy with vitamin K antagonist (VKA), antiplatelet therapy with ASA, or both VKA and ASA.
Methods
Retrospective we investigated the development of recurrence arterial thrombosis in 23 patients consecutive diagnosed in our hospital of APS with previous arterial thrombosis, from 1 February 2000 to 31 December of 2015. The patients ages were between 25 to 88, gender 39.1% male and 60.9%. Patients were treated well with ASA 100 or 300 mg either VKA for objective 2.5 INR, adding or ASA 100 mg depending on the thrombotic risk (depending on the location of thrombosis and the presence of thrombophilia and established cardiovascular risk factors ). 10 patients present Stroke, including Cryptogenic Ischemic Stroke, 6 present Transient Ischemic Attack, 4 Myocardial Infarction, and 3 other periferical arterial thrombosis (ocular, laberintical and popliteal). Of this 23 patients, suffered recurrence arterial thrombosis 4 of 12 were taking AAS, 4 of 8 patients taking VKA, and 1 of 3 taking VKA and ASA.The statistical analysis was performed with Pearson test realized by JMP 9.
Results
We not found statistically significant difference between the APS patients taking VKA, ASA or VKA and AAS and the development of recurrence arterial thrombosis (OR 0.12, IC 95% -0.21 –0.46, p=0.73).
Conclusion
Although we found more patients with APS development recurrence arterial thrombosis taking AAS than VKA, we cannot establish an association between recurrence of arterial thrombosis and treatment without VKA. The location of thrombosis and the presence of classical cardiovascular risk factors do not seem to be good predictors of thrombotic recurrence. Future studies that delineate thrombotic risk in APS and evaluate current and novel anticoagulants as well as non anticoagulant therapies are required
Session topic: E-poster
Abstract: PB2215
Type: Publication Only
Background
The optimal type and intensity of anticoagulant therapy for the treatment of Antipospholipid Syndrome (APS) remain controversial issues, particularly for arterial thrombosis.
Aims
We investigated if there are difference between the development of recurrence of arterial thrombosis on APS taking anticoagulant therapy with vitamin K antagonist (VKA), antiplatelet therapy with ASA, or both VKA and ASA.
Methods
Retrospective we investigated the development of recurrence arterial thrombosis in 23 patients consecutive diagnosed in our hospital of APS with previous arterial thrombosis, from 1 February 2000 to 31 December of 2015. The patients ages were between 25 to 88, gender 39.1% male and 60.9%. Patients were treated well with ASA 100 or 300 mg either VKA for objective 2.5 INR, adding or ASA 100 mg depending on the thrombotic risk (depending on the location of thrombosis and the presence of thrombophilia and established cardiovascular risk factors ). 10 patients present Stroke, including Cryptogenic Ischemic Stroke, 6 present Transient Ischemic Attack, 4 Myocardial Infarction, and 3 other periferical arterial thrombosis (ocular, laberintical and popliteal). Of this 23 patients, suffered recurrence arterial thrombosis 4 of 12 were taking AAS, 4 of 8 patients taking VKA, and 1 of 3 taking VKA and ASA.The statistical analysis was performed with Pearson test realized by JMP 9.
Results
We not found statistically significant difference between the APS patients taking VKA, ASA or VKA and AAS and the development of recurrence arterial thrombosis (OR 0.12, IC 95% -0.21 –0.46, p=0.73).
Conclusion
Although we found more patients with APS development recurrence arterial thrombosis taking AAS than VKA, we cannot establish an association between recurrence of arterial thrombosis and treatment without VKA. The location of thrombosis and the presence of classical cardiovascular risk factors do not seem to be good predictors of thrombotic recurrence. Future studies that delineate thrombotic risk in APS and evaluate current and novel anticoagulants as well as non anticoagulant therapies are required
Session topic: E-poster
Type: Publication Only
Background
The optimal type and intensity of anticoagulant therapy for the treatment of Antipospholipid Syndrome (APS) remain controversial issues, particularly for arterial thrombosis.
Aims
We investigated if there are difference between the development of recurrence of arterial thrombosis on APS taking anticoagulant therapy with vitamin K antagonist (VKA), antiplatelet therapy with ASA, or both VKA and ASA.
Methods
Retrospective we investigated the development of recurrence arterial thrombosis in 23 patients consecutive diagnosed in our hospital of APS with previous arterial thrombosis, from 1 February 2000 to 31 December of 2015. The patients ages were between 25 to 88, gender 39.1% male and 60.9%. Patients were treated well with ASA 100 or 300 mg either VKA for objective 2.5 INR, adding or ASA 100 mg depending on the thrombotic risk (depending on the location of thrombosis and the presence of thrombophilia and established cardiovascular risk factors ). 10 patients present Stroke, including Cryptogenic Ischemic Stroke, 6 present Transient Ischemic Attack, 4 Myocardial Infarction, and 3 other periferical arterial thrombosis (ocular, laberintical and popliteal). Of this 23 patients, suffered recurrence arterial thrombosis 4 of 12 were taking AAS, 4 of 8 patients taking VKA, and 1 of 3 taking VKA and ASA.The statistical analysis was performed with Pearson test realized by JMP 9.
Results
We not found statistically significant difference between the APS patients taking VKA, ASA or VKA and AAS and the development of recurrence arterial thrombosis (OR 0.12, IC 95% -0.21 –0.46, p=0.73).
Conclusion
Although we found more patients with APS development recurrence arterial thrombosis taking AAS than VKA, we cannot establish an association between recurrence of arterial thrombosis and treatment without VKA. The location of thrombosis and the presence of classical cardiovascular risk factors do not seem to be good predictors of thrombotic recurrence. Future studies that delineate thrombotic risk in APS and evaluate current and novel anticoagulants as well as non anticoagulant therapies are required
Session topic: E-poster
{{ help_message }}
{{filter}}